FDA Approves Dectomax-CA1 for Treatment and Prevention of NWS Infestations in Cattle
U.S. Food and Drug Administration (FDA) shared on LinkedIn:
”Today, we conditionally approved the first drug for the prevention and treatment of New World screwworm (NWS) larval infestations as well as the prevention of NWS reinfestation for 21 days.
This conditional approval is limited for use in cattle and demonstrates the Agency’s dedication to rapidly facilitating access to important animal health products.”
New World Screwworm infestations, first re-emerging in Central America in 2024, have spread north through Mexico in 2025, with cases now detected as far as Nuevo Leon near the U.S. border.
The outbreak threatens regional cattle industries, prompting livestock movement restrictions, sterile fly release programs, and strict U.S.–Mexico border surveillance.
On September 30, 2025, the U.S. Food and Drug Administration conditionally approved Dectomax-CA1 for the prevention and treatment of New World screwworm (NWS) larval infestations in cattle.
The drug is available as an injectable solution and provides protection against reinfestation for up to 21 days.
Doramectin, the active ingredient, is a macrocyclic lactone that targets the parasite’s nervous system by selectively binding to glutamate-gated chloride channels.
This binding leads to hyperpolarization of nerve and muscle membranes, resulting in paralysis and death of the parasite.
Its longer half-life, due to greater lipophilicity and enhanced tissue distribution, underlies its prolonged activity, which represents a key advantage over other similar agents.
Read more on the topic here.
More on latest FDA approvals in the field of Hematology featured in Hemostasis Today.
-
Oct 3, 2025, 07:53Pancytopenia in Pregnancy: A Time-Critical Hematological Emergency
-
Oct 2, 2025, 14:12Helen McPherson at ISFP-IFRS 2025: Fibrin Clot Structure and Function Modulation by Targeting Fibrinogen aC Region
-
Oct 2, 2025, 10:48Kanishk Kumar: TFPI Market Size - Advancing Hemostasis and Antithrombotic Therapy
-
Oct 2, 2025, 07:31Non-Invasive Management of Radial Artery Pseudoaneurysm
-
Oct 2, 2025, 07:28Mohamed Gamal: Rethinking The Standard of Care for Deep Vein Thrombosis Management
-
Oct 3, 2025, 14:00Quentin Van Thillo Shares His Latest Article on VWD: Grateful to Have Worked with Cedric Hermans
-
Oct 3, 2025, 13:40Cihan Ay and Colleagues on Thromboembolism and Bleeding in Multiple Myeloma
-
Oct 3, 2025, 13:27Laura Haynes: This Was Such a Fun and Collaborative Project to Be a Part of!
-
Oct 3, 2025, 12:40Christian Pfrepper and Team's Letter on Emicizumab Plasma Concentration Measurment in EDTA plasma
-
Oct 3, 2025, 12:00Giuseppe Lippi and Colleagues on the Impact of Hemolysis on Coagulation Testing
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 1, 2025, 15:59Anirban Sen Gupta: Thrilled to share a great collaboration story in Nature Portfolio
-
Oct 3, 2025, 14:48Maha Othman - Elected as the Co-Lead for the Basic and Translational Research Platform at CanVECTOR Research Network
-
Oct 3, 2025, 14:41Maria Elisa Mancuso: A Real Pleasure to Participate in The Policy Roundtable on Future of Haemophilia Care in Egypt
-
Oct 2, 2025, 04:37Louise Bannon: Did You Know that 1 in 4 People Lose Their Lives to Blood Clot-Related Conditions?
-
Oct 1, 2025, 16:35World Thrombosis Day 2025․ 8 Ways to Take Control and Save Lives
-
Oct 1, 2025, 12:30World Stroke Academy "Antithrombotic Therapy for Atherosclerotic Stroke Prevention" Webinar is Now Available to Record